Formycon AG (FRA:FYB)
22.75
-0.15 (-0.66%)
Last updated: Sep 10, 2025, 10:03 AM CET
Formycon AG Revenue
Formycon AG had revenue of 9.00M EUR in the half year ending June 30, 2025, a decrease of -79.45%. This brings the company's revenue in the last twelve months to 51.78M, down -14.84% year-over-year. In the year 2024, Formycon AG had annual revenue of 69.67M, down -10.32%.
Revenue (ttm)
51.78M
Revenue Growth
-14.84%
P/S Ratio
7.81
Revenue / Employee
211.34K
Employees
250
Market Cap
404.52M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 69.67M | -8.02M | -10.32% |
Dec 31, 2023 | 77.70M | 35.20M | 82.83% |
Dec 31, 2022 | 42.50M | 5.88M | 16.07% |
Dec 31, 2021 | 36.61M | 2.32M | 6.76% |
Dec 31, 2020 | 34.30M | 1.14M | 3.43% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.89B |
Siemens Aktiengesellschaft | 78.30B |
Deutsche Telekom AG | 120.55B |
Allianz SE | 109.02B |
Rheinmetall AG | 10.67B |
Siemens Energy AG | 38.39B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.33B |
Deutsche Bank Aktiengesellschaft | 30.07B |
Formycon AG News
- 4 weeks ago - Formycon Boosts Working Capital, Stays on Track for Year-End Goals - Wallstreet:Online
- 4 weeks ago - EQS-News: Formycon confirms full-year guidance following business development in line with plan – working capital raised - Wallstreet:Online
- 6 weeks ago - EQS-News: Formycon invites to conference call on 2025 half-year results and announces participation in international investor conferences in the 3rd quarter of 2025 - Wallstreet:Online
- 2 months ago - EQS-AFR: Formycon AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] - Wallstreet:Online
- 2 months ago - EQS-News: Formycon successfully completes patient enrollment for the clinical development of its Keytruda biosimilar candidate FYB206 - Wallstreet:Online
- 2 months ago - EQS-News: Bio Usawa becomes partner for the commercialization of FYB201/ BioUcenta (ranibizumab) across Sub-Saharan Africa - Wallstreet:Online
- 2 months ago - EQS-Adhoc: Formycon successfully places an EUR 70 million senior unsecured floating rate bond - Wallstreet:Online
- 2 months ago - EQS-News: Teva becomes secondary commercialization partner for Formycon's Stelara biosimilar FYB202 (ustekinumab) under the brand name Fymskina in Germany - Wallstreet:Online